Breast cancer immunophenotype dynamic change

Aim. Comparative analysis of primary breast cancer and breast cancer local relapse phenotypes. Methods. 5808 patients with confirmed diagnosis of breast cancer, including 108 (1,86%) with local relapses, underwent surgical treatment from 2000 since 2011. 26 tumors were prospectively examined by histological and immunohistochemical methods using monoclonal antibodies to estrogen and progesterone receptors and to Her2/neu oncogene protein. Results were compared with corresponding parameters of primary tumours. Results. Local relapses occurred in 1,2% of cases after total mastectomy, and in 5,1% - after incomplete mastectomy. Surgical approach to patients with local relapse of breast cancer depended on tumor size. Ectomy of the relapsing tumor at the post-operation scar site or at anterior chest wall was preformed in 60 (55,6%) cases, simple mastectomy after incomplete mastectomy - in 33 (30,5%) cases, repeated incomplete mastectomy with breast reconstruction - in 12 (11,1%) cases, and loco-regional relapsing tumor ectomy - in 3 (2,8%) cases. Immunohistochemical phenotypes of primary and relapsing tumors were different in 15 out of 26 studied cases. Switch from hormone-negative to hormone-positive tumor was registered in 46,7% of cases, from hormone-positive to hormone-negative tumor - in 40%, isolated change of Her2/neu oncogene protein expression - in 13,3%. Conclusion. The hypothesis of change of breast cancer phenotype after treatment has been confirmed; changes of immunohistochemical parameters after the local relapse should be taken into consideration for defining the treatment tactics.

Download Full-text

METAPLASTIC CARCINOMA OF BREAST : A CASE REPORT

10.36106/paripex/2601323 ◽

2021 ◽

pp. 39-40

Author(s):

Manju Singh ◽

S N Gole ◽

S L Nirala ◽

T Narasimha Murty

Keyword(s):

Breast Cancer ◽

Progesterone Receptors ◽

Left Breast ◽

Metaplastic Carcinoma ◽

Axillary Lymph Nodes ◽

Axillary Lymph ◽

Metaplastic Breast Cancer ◽

Biopsy Report ◽

Simple Mastectomy ◽

Cell Variant

Metaplastic breast cancer constitute nearly 1 % of all breast carcinoma cases. There is metaplasia of normal epithelial components of the breast into other types. They are highly aggressive with very poor prognosis. Here we present a case of 30 year old female who presented with a breast lump in her left breast associated with dull aching pain. It was 10 x 10 cm in size involving upper inner, upper outer, lower outer quadrants and retroareolar area of left breast. USG was suugestive of BIRADS VI lesion. Axillary lymph nodes were not found enlarged clinically or radiologically. Core biopsy report showed Phylloides tumor of breast. The patient underwent simple mastectomy of left breast and histopathology revealed spindle cell variant of metaplastic breast cancer. The cell blocks sent for immunohistochemistry were negative for estrogen, progesterone receptors and Her2neu receptor. The post surgical treatment of this type of breast cancer is still under study.

Download Full-text

HER-2/neu oncogene protein and prognosis in breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.1989.7.8.1120 ◽

1989 ◽

Vol 7 (8) ◽

pp. 1120-1128 ◽

Cited By ~ 385

Author(s):

A K Tandon ◽

G M Clark ◽

G C Chamness ◽

A Ullrich ◽

W L McGuire

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Clinical Outcome ◽

Node Negative ◽

Node Positive ◽

Her 2 ◽

Neu Oncogene ◽

Disease Free ◽

Oncogene Protein ◽

Positive Breast Cancer

Amplification of the HER-2/neu oncogene was recently reported to predict poor clinical outcome in node-positive breast cancer patients. Since expression of the oncogene as its protein product might be even more closely related than gene amplification to disease progression, we have now examined levels of the HER-2/neu oncogene protein for its prognostic potential in both node-positive and node-negative breast cancer. Using Western blot analysis, levels of this protein were determined in 728 primary human breast tumor specimens. We examined relationships between this protein and other established markers of prognosis, as well as clinical outcome. In node-negative patients (n = 378), the HER-2/neu protein failed to predict disease outcome. However, in node-positive patients (n = 350), those patients with higher HER-2/neu protein had statistically shorter disease-free (P = .0014) and overall survival (P less than .0001) than patients with lower levels of the protein. Higher HER-2/neu protein was found in tumors without estrogen receptor (ER) (P = .02) or progesterone receptor (PgR) (P = .0003), and in patients with more than three positive lymph nodes (P = .04). A significant correlation between levels of the HER-2/neu gene protein and amplification of the gene itself was also found (n = 48, P less than .001). Multivariate analyses in these patients showed that the HER-2/neu protein is a significant independent predictor of both the disease-free and the overall survival in node-positive breast cancer, even when other prognostic factors are considered.

Download Full-text

NEGATIVE PROGESTERONE RECEPTORS PROGNOSTIC SIGNIFICANCE WITHIN POSITIVE ESTROGEN RECEPTORS PRE-MENOPAUSAL BREAST CANCER

10.26226/morressier.5770e29ad462b80290b4caba ◽

2016 ◽

Author(s):

Simone Subtil

Keyword(s):

Breast Cancer ◽

Estrogen Receptors ◽

Prognostic Significance ◽

Progesterone Receptors

Download Full-text

Age-Related Biology of Early-Stage Operable Breast Cancer and Its Impact on Clinical Outcome

Cancers ◽

10.3390/cancers13061417 ◽

2021 ◽

Vol 13 (6) ◽

pp. 1417

Author(s):

Binafsha M. Syed ◽

Andrew R. Green ◽

Emad A. Rakha ◽

David A.L. Morgan ◽

Ian O. Ellis ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Histological Grade ◽

Survival Rates ◽

Growth Factor Receptor ◽

Progesterone Receptors ◽

Biological Characteristics ◽

Cancer Specific Survival ◽

Age Related ◽

Significant Difference

As age advances, breast cancer (BC) tends to change its biological characteristics. This study aimed to explore the natural progression of such changes. The study included 2383 women with clinically T0-2N0-1M0 BC, managed by primary surgery and optimal adjuvant therapy in a dedicated BC facility. Tissue micro-arrays were constructed from their surgical specimens and indirect immunohistochemistry was used for analysis of a large panel (n = 16) of relevant biomarkers. There were significant changes in the pattern of expression of biomarkers related to luminal (oestrogen receptor (ER), progesterone receptors (PgR), human epidermal growth factor receptor (HER-2), E-cadherin, MUC1, bcl2 CK7/8, CK18 and bcl2) and basal (CK5/6, CK14, p53 and Ki67) phenotypes, lymph node stage, histological grade and pathological size when decade-wise comparison was made (p < 0.05). The ages of 40 years and 70 years appeared to be the milestones marking a change of the pattern. There were significantly higher metastasis free and breast cancer specific survival rates among older women with ER positive tumours while there was no significant difference in the ER negative group according to age. Biological characteristics of BC show a pattern of change with advancing age, where 40 years and 70 years appear as important milestones. The pattern suggests <40 years as the phase with aggressive phenotypes, >70 years as the less aggressive phase and 40–70 years being the transitional phase.

Download Full-text

Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer

Cancers ◽

10.3390/cancers13143427 ◽

2021 ◽

Vol 13 (14) ◽

pp. 3427

Author(s):

Reyhaneh Farghadani ◽

Rakesh Naidu

Keyword(s):

Breast Cancer ◽

Signaling Pathways ◽

Mapk Pathway ◽

Growth Factor Receptor ◽

Progesterone Receptors ◽

Drug Candidate ◽

Molecular Signaling ◽

Her2 Positive ◽

Therapeutic Implications ◽

Epidermal Growth

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among women worldwide. Despite the overall successes in breast cancer therapy, hormone-independent HER2 negative breast cancer, also known as triple negative breast cancer (TNBC), lacking estrogens and progesterone receptors and with an excessive expression of human epidermal growth factor receptor 2 (HER2), along with the hormone-independent HER2 positive subtype, still remain major challenges in breast cancer treatment. Due to their poor prognoses, aggressive phenotype, and highly metastasis features, new alternative therapies have become an urgent clinical need. One of the most noteworthy phytochemicals, curcumin, has attracted enormous attention as a promising drug candidate in breast cancer prevention and treatment due to its multi-targeting effect. Curcumin interrupts major stages of tumorigenesis including cell proliferation, survival, angiogenesis, and metastasis in hormone-independent breast cancer through the modulation of multiple signaling pathways. The current review has highlighted the anticancer activity of curcumin in hormone-independent breast cancer via focusing on its impact on key signaling pathways including the PI3K/Akt/mTOR pathway, JAK/STAT pathway, MAPK pathway, NF-ĸB pathway, p53 pathway, and Wnt/β-catenin, as well as apoptotic and cell cycle pathways. Besides, its therapeutic implications in clinical trials are here presented.

Download Full-text

Selective Targeting of Breast Cancer by Tafuramycin a Using SMA-Nanoassemblies

Molecules ◽

10.3390/molecules26123532 ◽

2021 ◽

Vol 26 (12) ◽

pp. 3532

Author(s):

Ibrahim M. El-Deeb ◽

Valeria Pittala ◽

Diab Eltayeb ◽

Khaled Greish

Keyword(s):

Breast Cancer ◽

Progesterone Receptors ◽

In Vivo Studies ◽

Chemotherapy Agent ◽

Anticancer Effects ◽

Tumor Tissues ◽

Potential Strategy ◽

Tumor Accumulation

Triple-negative breast cancer (TNBC) is a heterogeneous subtype of tumors that tests negative for estrogen receptors, progesterone receptors, and excess HER2 protein. The mainstay of treatment remains chemotherapy, but the therapeutic outcome remains inadequate. This paper investigates the potential of a duocarmycin derivative, tafuramycin A (TFA), as a new and more effective chemotherapy agent in TNBC treatment. To this extent, we optimized the chemical synthesis of TFA, and we encapsulated TFA in a micellar system to reduce side effects and increase tumor accumulation. In vitro and in vivo studies suggest that both TFA and SMA–TFA possess high anticancer effects in TNBC models. Finally, the encapsulation of TFA offered a preferential avenue to tumor accumulation by increasing its concentration at the tumor tissues by around four times in comparison with the free drug. Overall, the results provide a new potential strategy useful for TNBC treatment.

Download Full-text